Full Title15MUDD: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
In this study, researchers are evaluating the use of the anticancer drug cyclophosphamide given after a human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplant in patients with blood cancers to see if it can reduce the risk of transplant rejection and graft-versus-host disease. They will also assess recipients’ survival, rate of cancer recurrence, and post-transplant complications. Patients will also receive two other anti-rejection drugs after transplantation: sirolimus and mycophenolate mofetil.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have acute leukemia, lymphoma, myelodysplastic syndromes, or chronic lymphocytic leukemia that will be treated with mismatched unrelated bone marrow transplantation.
- Patients who have had a prior allogeneic (donated) bone marrow transplant may not participate.
- This study is for patients ages 18 to 70.